论文部分内容阅读
目的评价伏立康唑和伊曲康唑治疗老年恶性肿瘤合并肺部真菌感染的临床疗效和安全性。方法回顾性分析60例老年恶性肿瘤合并肺部真菌感染患者的临床资料,其中29例患者采用伏立康唑注射液治疗(伏立康唑组),31例患者采用伊曲康唑注射液治疗(伊曲康唑组),比较两种治疗方式的临床有效率和不良反应。结果伏立康唑组患者的有效率和不良反应率发生率分别为82.8%和13.8%,伊曲康唑组患者的有效率和不良反应发生率分别为70.9%和25.8%,两组患者比较,差异有统计学意义(P<0.05)。结论伏立康唑治疗老年恶性肿瘤合并肺部真菌感染的临床疗效优于伊曲康唑,安全性好,值得临床进一步推广。
Objective To evaluate the clinical efficacy and safety of voriconazole and itraconazole in the treatment of elderly patients with malignant pulmonary fungal infection. Methods The clinical data of 60 elderly patients with malignant neoplasm associated with pulmonary fungal infection were retrospectively analyzed. Among them, 29 patients were treated with voriconazole (voriconazole), and 31 patients were treated with itraconazole ), Comparing the clinical efficacy and adverse reactions of the two treatment methods. Results The incidence rates of vasopressin and vasopressin in the voriconazole group were 82.8% and 13.8%, respectively, and those in itraconazole group were 70.9% and 25.8% respectively. There was significant difference between the two groups Statistical significance (P <0.05). Conclusion Voriconazole is superior to itraconazole in the treatment of elderly patients with malignant pulmonary fungal infection. It is safe and worthy of further clinical application.